Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFFECTS Study: Everolimus Expanded Access in TSC-Associated SEGA
2010-022583-13Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of everolimus in astrocytoma and tuberous sclerosis complex (TSC), sponsored by Novartis. Primary endpoints: Safety of everolimus and Investigator’s best overall response rate. Started Dec 2010; status: completed.
02
Drugs
everolimus
03
Conditions
astrocytomatuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on 2010-022583-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022583-13.